去纤维钠作用及功效

(Defibrotide, defiteli) is a mixture of single-stranded oligonucleotides broken down from genomic DNA from calf lung or pig intestinal mucosa. The oligonucleotide chain length of defibrinated sodium varies, the relative molecular mass is between 15×10³-30×10³, and its purine to pyrimidine ratio is greater than 0.85. The mechanism of action of defibrinated sodium is relatively complex and is not yet fully understood. Preclinical tests have confirmed that defibrinated sodium has anti-thrombotic, fibrinolytic, anti-ischemic, and anti-infective effects in vivo and in vitro.

Function and efficacy of defibrinated sodium:

A large series of prospective clinical studies included 305 patients with HVOD after HSCT, with a median age of 16 years (0.1-70 years), including 220 patients with sHVOD. The therapeutic dose of defibrotide sodium (defiteli) is 25 mg/kg per day, intravenous infusion. Preliminary results show that: the complete response (CR) rate is 30%, and the overall survival (OS) rate 100 days after transplantation is 50%; the CR rate of sHVOD patients is 26%, and the OS rate 100 days after transplantation is 45%; the CR rate of non-sHVOD patients is 39%, and the OS rate 100 days after transplantation is 65%. The CR rates of pediatric and adult patients were 33% and 26%, respectively (P=0.187), and the OS rates 100 days after transplantation were 56% and 44%, respectively (P=0.0277).

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide sodium (defiteli) has obvious effects and has significantly increased the 100-day OS rate of patients in clinical trials. It is also well tolerated and is a good choice for patients.

The above is an introduction to the function and efficacy of (defiteli), I hope it will be helpful to you.